IL10 and carcinoma: Interestingly, from the pathologist’s report, one of the lung tumours had a PD-L1 score of 55% (i.e. 55% of tumour cells demonstrated positive immunoreactivity for PD-L1 determined by immunohistochemistry) and the dissociated cells from this carcinoma demonstrated a particularly robust response (increased secretion of IFNγ and IL-10) to anti-PD-1 treatment in the presence of mature DCs (Supplementary Fig. S4 online) relative to isotype control.